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1. Introduction 
The past decades have seen considerable advances in our understanding of the 
developmental mechanisms of neurodegenerative disorders, including Parkinson’s, 
Alzheimer’s and Huntington’s diseases and spinal cord injury [1-3]. The major 
neuropathological characteristics of neurodegenerative disorders are atrophy or loss of 
specific neurons in the specific brain areas, such as cholinergic neuron degeneration 
observed in the basal forebrain, hippocampus and cortex in Alzheimer’s disease (AD) and 
dopaminergic neuron degeneration observed in the striatum in Parkinson’s disease [4-6]. As 
the life span of human beings increases and more people live beyond the age of 60, the 
number of people with neurodegenerative disorders is also progressively increased. 
Contrasting with the enormous toll that these disorders put on patients, their caregivers and 
the whole society is the lack of effective therapy at present.  
Neurotrophic factors (NTFs) are secreted peptides essential for the phenotypic development 
and maintenance of specific neuronal populations in developing and adult vertebrate 
nervous system [7-14]. These diffusible proteins act via retrograde signaling from target-
neurons and by paracrine and autocrine mechanisms, and regulate many aspects of 
neuronal and glial structure and function. In addition to playing key roles during 
development, NTFs are also required in the adult brain for maintaining neuronal function 
and phenotype. Previous studies of intracerebroventricular (ICV) administration of NTFs 
have shown to reduce or prevent neuronal atrophy or neuronal loss in neurodegenerative 
diseases [7-9, 12, 13, 15, 16]. The cholinergic neurons of basal forbrain express both the low 
affinity receptor (p75NTR) and high affinity receptor (Trk receptor), and respond to 
neurotrophic factors by increased activity levels of the choline acetyltransferase (ChAT). 
NTFs exert neurotrophic actions on the cholinergic neurons of the basal forebrain and 
protect them against neurodegeneration [7, 12, 15, 17]. For example, ICV injection of nerve 
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growth factor (NGF) has shown to improve the learning and memory ability, and the 
survival of basal forebrain cholinergic neurons in aged or fimbria-fornix lesioned animals. 
Furthermore, NTFs have been used for the experimental therapies in Parkinson’s, 
Alzheimer’s and Huntington’s diseases  and spinal cord injury [4-14]. 
Modern biotechnology has enabled  the large-scale production of highly purified proteins; 
therefore, large quantities of growth factors can now be manufactured for clinical use. 
However, NTFs are large molecular proteins that do not readily cross the blood–brain barrier 
(BBB), and have short biologic half-life [10-13]. To improve their therapeutic efficacy and 
patient compliance, local and controlled delivery of NTFs directly to the desired brain area are 
preferred [3, 18-20]. NGF-releasing and glial cell line-derived neurotrophic factor (GDNF)-
releasing microspheres have been developed for the experimental therapy of Alzheimer’s and 
Parkinson’s disease (PD) [21-30]. Compared to other exiting approaches, the strategy based on 
biodegradable microspheres has demonstrated a number of advantages. 
 Ease of administration to the targeted area of the brain, thus avoiding open operation 
and damage to surrounding tissue [31, 32]. 
 Preservation of drug activity during encapsulation and storage. 
 Localized, controlled-release profiles for a desired period, resulting in enhanced 
therapeutic effect while minimizing side effects.  
 Better safety profiles, as compared with gene therapy such as gene delivery and 
transplantation of genetically modified cells. 
In this chapter, to serve as a good example, we presented our previous works focusing on 
the formulation and characterization of NGF-loaded microspheres. The in vivo efficacy of 
these microspheres was evaluated in a rat model of AD. The methods described here can be 
applied broadly to other types of NTF-releasing microspheres. 
2. Materials 
2.1 Formulation of NGF-releasing microspheres 
General regents and instruments for the preparation of NGF-releasing microspheres, the 
abbreviations and source of these reagents are as follows: 
2.1.1 Neurotrophic factors such as human recombinant β-nerve growth factor (NGF) 
(Calbiochem or Sigma) 
2.1.2 Poly(lactide-co-glycolide) (PLGA) (lactic acid/glycolic acid = 75/25) (Birmingham 
Polymers Inc. or Sigma) 
2.1.3 Bovine serum albumin (BSA) or human serum albumin (HSA) (Calbiochem or Sigma). 
2.1.4 FITC-labeled BSA (FITC-BSA) (Sigma) 
2.1.5 Polyvinyl alcohol (PVA) (Sigma). 
2.1.6 Acetone (Sigma) 
2.1.7 Methylene chloride (Sigma) 
2.1.8 Sonicator (Sonics & materials INC. USA) 
www.intechopen.com
Controlled Release Strategy  
Based on Biodegradable Microspheres for Neurodegenerative Disease Therapy 
 
49 
2.1.9 Cantilever agitator (IKA. RW20 DZM.n, Guangzhou Scientific Instrument, Ltd Co) 
2.2 Characterization of NGF-releasing Microspheres  
Instruments for microsphere characterization, the abbreviations and source of these reagents 
are as follows: 
2.2.1 Coulter counter (model ZM, Coulter Electronics Limited, UK) 
2.2.2 Scanning electron microscopy (XL30ESEM, Philips, Netherlands) 
2.2.3 Rabbit anti-rhNGF-beta polyclonal antibody and CY3-conjugated goat anti-rabbit 
secondary antibody (Chemicon) 
2.2.4 Ultraviolet spectrophotometer (Hach) 
2.2.5 Confocal laser scanning microscopy (CLSM; Leica TCS SP5, Leica Mikrosysteme 
Vertrieb GmbH, Germany) 
2.3 Cell culture 
General Regents for PC12 cell culture, the abbreviations and source of these reagents are as 
follows: 
2.3.1 Dulbecco Modified Eagle’s medium (DMEM) (Invitrogen) 
2.3.2 Fetal bovine serum (FBS) (Invitrogen) 
2.3.3 Fetal horse serum (FHS) (Invitrogen) 
2.3.4 Trypsin-EDTA (1x) (Invitrogen) 
2.3.5 Penicillin/Streptomycin (100x) (Invitrogen) 
2.3.6 L-glutamine (100x) (Invitrogen) 
2.4 Evaluation of in vivo efficacy in a rat model of AD 
Normotensive adult male Sprague Dawley (SD) rats weighing 250-300 g are used. The general 
tools, instruments and reagents for in vivo evaluation in a rat model of AD are as follows: 
2.4.1 Narishige stereotaxic instrument (Narishige SR-5, Narishige Scientific Instrument Lab, 
Tokyo, Japan) 
2.4.2 One scalpel size 3 with No. 10 blade 
2.4.3 Two small scissors for blunt dissection 
2.4.4 One needle holder 
2.4.5 One pair of microsurgical scissors 
2.4.6 Two pairs of microsurgical forceps 
2.4.7 3/0 sutures 
2.4.8 Dentistry drill 
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2.5 Tissue processing 
2.5.1 Ice-cold phosphate buffered saline (PBS) 
2.5.2 Ice-cold saline. 
2.5.3 15% and 30% sucrose in PBS 
2.5.4 4% paraformaldehyde  
2.5.5 Serum infusion set with a blunted 20-ga needle 
2.5.6 OCT Tissue freezing medium 
2.5.7 Anti-rhNGF antibody, anti-Choline acetyltransferase (ChAT) antibody and appropriate 
secondary antibodies 
2.5.8 Image J software (National Institutes of Health) 
2.6 Assessment of learning and memory impairment 
2.6.1 Y-maze test (Chongqing Medical Apparatus Co, China) 
3. Methods 
3.1 Preparation of NGF-releasing microspheres 
NGF-releasing microspheres were formulated using with a modified multiple emulsion 
solvent extraction-evaporation technique (W/O/W) (see Note 1) [24]. NGF (5-10 mg) (see 
Note 2) and BSA (1/50-2000, w/w) in 100-200 µL distilled water. The protein solution was 
emulsified in a solution of PLGA (100-200 mg) (see Note 3) in methylene chloride/acetone 
(3/1, 4-8 mL) to form the first W/O emulsion (see Note 4), using sonication for 1-2 min at 
20-40 W over an ice bath. The first W/O emulsion was then added to 1% PVA aqueous 
solution (25-50 mL) (see Note 5), and homogenized at 800-2000 rpm for 5-10 min over an ice 
bath to form W/O/W double emulsion. The W/O/W double emulsion was stirred at room 
temperature for 3-4 h to allow the evaporation of the organic solvents in the fume hood. The 
microspheres were collected by centrifugation, and washed three times with distilled water 
to remove any proteins that were weakly bound onto the surface of microspheres. The 
harvested microspheres were freeze-dried to obtain a free flowing powder. The NGF/FITC-
BSA-releasing microspheres were prepared using in the same way for in vivo release and 
tracking studies (see Note 6 and 7). 
3.2 Characterization of NGF-releasing microspheres 
3.2.1 The size distribution of NGF-releasing microspheres was measured using a Coulter 
counter  
3.2.2 The morphology of NGF-releasing microspheres was examined using scanning 
electron microscopy (SEM) 
The freeze-dried NGF-releasing microspheres were mounted on the conductive tap of a 
metal stub, and sputtered coated with gold before being observed using SEM (Figure 1). 
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Fig. 1. SEM micrographs of NGF-releasing microspheres after various intervals of 
incubation in PBS. (A) The microspheres were spherical in shape with smooth surface before 
incubation with PBS. (B) After 1 week of incubation, shallow pores appeared on the surface 
of the microspheres that maintained intact spherical shape. (C) After incubation for 3 weeks, 
the microspheres showed highly porous surfaces and irregular shapes, with eroded inner 
matrix. (D) After incubation for 5 weeks, most of the microspheres lost their spherical shape 
and collapsed. This picture was taken from our previous paper and allowed to use here by 
Polymer International.  
 
Fig. 2. Confocal Laser Scanning Microscopy (CLSM) micrographs of NGF/FITC-BSA-
releasing microspheres at lower magnification (A) and higher magnification (B). This picture 
was taken from our previous paper and allowed to use here by Polymer International. 
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3.2.3 The morphology of NGF/FITC-BSA-releasing microspheres was examined by confocal 
laser scanning microscopy (CLSM)  
Freeze-dried NGF/FITC-BSA-releasing microspheres spread on glass coverslips were 
observed under CLSM (Figure 2). 
3.2.4 The amount of the protein encapsulated in the NGF/BSA-releasing microspheres was 
determined by a protein extraction method described below  
Ten to thirty milligrams of microspheres were dissolved in 1-2 mL of chloroform and 
extracted with 4 mL of deionized water. The mixture was vortex for 5-10 min. The extracted 
protein in aqueous phase was separated and collected by centrifugation. Three extractions 
were performed for each sample. The aqueous extracts were pooled together, and the 
protein concentration was determined by BCA microassay. Experiments were run in 
triplicate per sample. The protein loading and encapsulation efficiency in microspheres 
were defined by the following equations: 
Protein loading in microspheres (%) = Weight of protein in the aqueous extract/Weight of 
microspheres extracted × 100  
Encapsulation efficiency (%) = Weight of protein in microspheres/Weight of protein in the 
initial formulation × 100 
3.2.5 In vitro release of NGF 
In vitro drug release from the NGF-releasing microspheres was monitored  in PBS at 37oC, 
utilizing double-chamber diffusion cells on a shaker stand. Approximately 50 mg of the 
microspheres were suspended in 4 mL of PBS buffer in the donor chamber. The receiver 
chamber was filled with 4 mL plain buffer. The donor chamber and receiver chamber were 
separated with 0.45 µm low-protein absorbable membrane. At predetermined time points, 
the PBS buffer in the receiver chamber was collected and replaced with same amount of 
fresh PBS. The protein concentration in the collected buffer solution was analyzed using 
BCA microassay. The concentration of the released NGF in the buffer solution was 
measured using ELISA and the amount of released NGF was calculated. Experiments were 
run in triplicate per sample. 
The bioactivity of the released NGF from the microspheres was assessed using PC12 cell 
culture. PC12 cells were maintained in growth on T-25 cell culture flasks (Corning Inc., 
Corning, NY) in RPMI 1640 supplemented with 10 wt% horse serum, 5 wt% fetal bovine 
serum and 50 U mL−1 penicillin/streptomycin. For the bioactivity of released NGF testing, 
PC12 cells were plated on poly (L-lysine) pre-coated 24-well plates. The cells were cultured 
at 37oC in a 95% water-saturated, 5% CO2 air atmosphere and plated at a density of 
approximately 1.0 × 104 cells/cm2 (in 2 mL). Twenty-four hours, 2 mL solution of in vitro 
NGF release buffer collected in the first week was sterile-filtered through a 0.22 μm filter 
(Millipore) and incubated with PC12 cells (30 ng mL−1). Incubating with NGF-supplement 
medium (30 ng mL−1) alone or with the released buffer from BSA-releasing microspheres 
(without NGF) served as positive or negative control, separately. To further confirm the 
bioactivity of the released NGF, anti-NGF antibody was added into the medium to 
neutralize the bioactivity of the released NGF.  
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Fig. 3. In vitro rhNGF release from rhNGF/BSA-loaded microspheres: with protein/PLGA 
(w/w) ratio of (▲) 5/100, (●) 10/100, and (■) 15/100. This picture was taken from our 
previous paper and allowed to use here by Polymer International. 
3.2.6 The bioactivity of the released NGF was test using PC 12 cells  
 
Fig. 4. The bioactivity of the released NGF from the PLGA microspheres as assessed with 
PC12 cell culture. (A) Positive control cells that were incubated with NGF-supplemented 
medium at a concentration of 30 ng mL−1; (B) the cells incubated with the released NGF 
from PLGA microspheres and added to the culture medium at a concentration of 30 ng 
mL−1; (C) negative control cells incubated with the released BSA from BSA-only PLGA 
microspheres and added to the culture medium ; (D) cells incubated with the released NGF-
supplemented culture medium plus anti-NGF antibody added . The percentage of neurite-
bearing cells was determined by counting 100–200 cells in several randomly chosen fields 
under an optical microscope for each sample after 24 h incubation. This picture was taken 
from our previous paper and allowed to use here by Polymer International. 
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Fig. 5. CLSM micrographs of NGF/FITC-BSA-loaded microspheres implanted in the BF (left 
column: observed under fluorescent filter; middle column: observed under normal light; 
right column: merged from left and middle): (A) 1 week after implantation, the fluorescent 
in implanted NGF/FITC-BSA-loaded microspheres is very strong; (B) 3 weeks after 
implantation, the fluorescent in implanted NGF/FITC-BSA-loaded microspheres became 
weak; (C) 4 weeks after implantation, the fluorescent in implanted NGF/FITC-BSA-loaded 
microspheres was weaker; (D) 5 weeks after implantation; most of the microspheres showed 
empty microspheres (black and white arrows showing an empty and a still-loaded 
microsphere, respectively). This picture was taken from our previous paper and allowed to 
use here by Polymer International. 
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3.2.7 In vivo tracking and release studies 
All experiments were carried out strictly according to the National Institute of Health Guide 
for the Care and Use of Laboratory Animals (NIH Publications No. 80-23) revised in 1996. 
All experiments were performed on adult male Sprague-Dawley (SD) rats (250–300 g) (see 
Note 8). The animals were housed in groups of two or three in macrolon cages; food and 
water were available ad libitum. All the animals were peritoneally anesthetized with 
sodium pentobarbital (40 mg kg−1 body weight) by peritoneal injection and positioned in a 
Narishige stereotaxic instrument (Narishige SR-5, Narishige Scientific Instrument Lab, 
Tokyo, Japan). An amount of 3 mg of NGF/FITC-BSA-loaded microspheres (suspended in 
10 μL of dispersing medium) was implanted into the BF (coordinates: anterior–posterior, 
+0.6 mm; left lateral, +0.6 mm; dorsal–ventral, −5.5 mm from bregma). 
At the predetermined time intervals, animals were perfused via the aorta with PBS (pH = 
7.4) 200 ml and fixed with 4 wt% paraformaldehyde for 30 min. The brains were removed 
and further fixed for 3-6 h at 4oC. The fixed brain was incubated in a 15 wt% sucrose buffer 
solution overnight and in 30 wt% sucrose buffer solution until it was sunk. Brain sections 
(20 μm) were cut at the transverse plane on a freezing microtome. These sections were 
mounted on gelatin-coated slides for directly examining the protein release from the 
NGF/FITC-BSA-loaded microspheres using CLSM. 
3.3 Recombinant human NGF-loaded microspheres implantation promotes survival of 
basal forebrain cholinergic neurons and improve memory impairments of spatial 
learning in the rat model of Alzheimer’s disease (see Note 9) 
Unilateral fimbria-fornix (FF) of SD rats was transected to simulate the impairment of 
cholinergic neurons of AD by the lesion of the septo-hippocampus pathway. The animals 
were randomly divided into four groups: (1) normal control group; (2) lesion control group; 
(3) unloaded microspheres group; (4) rhNGF-loaded microspheres group. At the lesion time, 
three milligrams of rhNGF-loaded microspheres (corresponding to 5 µg of NGF) (suspended 
in 10 µl of PBS) were stereotaxically implanted into the basal forbrain. 
At the predetermined time points, animals were perfused via the aorta with PBS (pH = 7.4) 
200 ml and fixed with 4 wt% paraformaldehyde for 30 min. The brains were removed and 
further fixed for 3-6 h at 4oC. The fixed brain was incubated in a 15 wt% sucrose buffer 
solution overnight and in 30 wt% sucrose buffer solution until it was sunk. Brain sections 
(30 μm) were cut at the transverse plane on a freezing microtome. The cholinergic neurons 
in medial septum (MS) and vertical diagonal band (VDB) were stained by ChAT 
immunohistochemistry. In brief, brain sections were incubated with 3% H2O2 to block 
endogenous peroxidase 30 min and then incubated in 10% normal goat serum for 1 h before 
incubation with rabbit anti-rat ChAT antibodies overnight at 4°C. Following primary 
antibody incubation, brain sections were washed with 1 × PBS, incubated with secondary 
antibody HRP-conjugated anti-rabbit IgG 1-2 h at room temperature and washed with 1 × 
PBS. And then brain sections were incubated with DAB. After incubated with gradient 
ethanol and xylene, the brain sections were mounted neutral permanent mounting medium.  
Y-maze test (see Note 10) was used to evaluate the ability of spatial learning and memory in 
different trial groups.  
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Fig. 6. Immunohistochemistry of cholinergic neurons show ChAT-positive in four groups in 
basal forebrain 4 weeks after microspheres implantation. (A and B) ChAT-positive in MS 
and VDB of the normal control group. (C and D) ChAT-positive in MS and VDB of the 
lesion control group. (E and F) ChAT-positive in MS and VDB of the unloaded microspheres 
group. (G and H) ChAT-positive in MS and VDB of the rhNGF-loaded microspheres group. 
Bar = 25 µm. This picture was from our previous paper and allowed to use here by 
Neuroscience letters. 
www.intechopen.com
Controlled Release Strategy  
Based on Biodegradable Microspheres for Neurodegenerative Disease Therapy 
 
57 
4. Notes 
The protocols given in this chapter are routinely conducted in our laboratory. The following 
notes may be of interest: 
1. Drug-releasing biodegradable polymeric microspheres are commonly prepared by 
physicochemical processes such as W/O/W emulsion solvent extraction-evaporation 
method, or mechanical processes such as spray coating, spray drying and spray 
congealing [33]. It is generally accepted that W/O/W emulsion solvent extraction-
evaporation technique is most suitable for encapsulation of proteins and peptides [25]. 
2. Based on the structure and function, neurotrophic factors (NTFs) are divided into 
several families: (1) nerve growth factor (NGF)-superfamily, including nerve growth 
factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), 
neurotrophin -4/5 (NT-4/5) and neurotrophin-6 (NT-6); (2) glial cell line-derived 
neurotrophic factor (GDNF) family, including glial cell line derived neurotrophic factor 
(GDNF), neurturin (NTN) and persephin (PSP); (3) neurokine superfamily, including 
ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), interleukin (IL) and 
cardiotrophin (CT); (4) non-neuronal growth factor-superfamily, including some 
members of fibroblast growth factor superfamily, epidermal growth factor (EGF) [10], 
insulin-like growth factor (IGF) [11, 14], bone morphogenetic protein (BMP) [2, 8, 12]. 
Furthermore, other growth factors also have neurotrophic function, such as vascular 
endothelial growth factor (VEGF) and erythropoietin (EPO) [34, 35]. Most of these 
neurotrophic factors are protein or glycoprotein and are suitable to prepare sustained 
release microspheres [22, 31, 36-39]. GDNF has been used to prepare sustained release 
microspheres and to use for the treatment of Parkinson’s disease [19, 21, 23, 25, 40]. 
Basic fibroblast growth factor (bFGF) has been used to formulate bFGF-loaded 
microshperes and use to treat ischemic hindlimb [27, 41, 42]. In central nervous system, 
different neurons have express different receptors and react with different neurotrophic 
factors. For example, cholinergic neurons express low affinity growth factor receptor 
(p75NGFR) and Trk receptor [20, 43]. 
3. PLGA belongs to a family of polyhydroxyalkanonate that have been extensively used in 
medical and pharmaceutical fields. It is biodegradable and biocompatible with brain 
tissue [44]. Drug release in PLGA based microspheres is modulated by both diffusion and 
degradation of polymer. The degradation process involves hydrolysis of the ester bonds, 
which is then autocatalyzed by the presence of acidic degradation products. The 
degradation rate of PLGA microspheres can range from less than one month to a few 
years, depending on the polymer composition (i.e. the molar ratio of lactic and glycolic 
acid units). This provides a convenient approach to engineering PLGA microspheres in 
order to provide a sustained and controlled release profile for a desired period to meet the 
clinical needs. Thus far, PLGA still remains the most popular polymer for the formulation 
of NTF-releasing microspheres. Several natural polymers have also been employed for the 
preparation of NTF-loaded microspheres. These includes hyaluronane derivatives [45], 
alginate-polylysine [46] and chitosan [47] etc. The application of these biomacromolecules 
needs to pay attention to the purity, batch-to-batch variation, and homogeneity of samples 
according to their origin. 
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4. A number of studies have indicated that the methylene chloride/water interface in the 
first emulsion step is detrimental to the structural integrity of protein, causing 
substantial conformational changes and protein denaturation [48, 49]. This denature 
effect could be overcome by optimizing the formulation parameters such as co-
encapsulation of BSA [49] and/or PEG 400 [50] as stabilizing agents, the use of low 
temperatures and short periods of sonication time.  
5. PVA has been intensively used as an emulsifier for the formulation of microspheres. 
Other polymeric surfactants such as polyvinylpyrrolidone (PVP) could serve as 
alternative emulsifier. Conway et al reported that microspheres formulated with PVP 
exhibited much higher protein loading and pronounced reduction in the “burst” release 
of protein [51]. However, research activity in this aspect is limited so far, especially in 
the application for neurodegenerative disease therapy. 
6. The formulation of NGF-releasing microspheres must be performed under aseptic 
conditions and using sterile starting materials. The current available sterilization 
methods such as autoclaving, -ray induced irradiation and ethylene oxide gas can 
induce protein degradation and/or toxicity.  
7. Recently nanospheres have attracted increasing attention in the delivery of growth 
factors [52]. Their much smaller sizes allow more effective internalization by cells via 
endocytic pathway, compared to microspheres. In the case of bioactive macromolecules 
that bind the membrane receptors to exert their functions, microspheres are more 
advantageous.  
8. Anesthesia with sodium pentobarbital is easy to apply by peritoneal injection. This 
anesthesia method is unexpensive and well tolerated by the animals. This method is 
simple, repeatable and can provide deep anesthesia more than 1 h that is usually 
enough for most of surgical procedures. The animals can be applied more this 
anesthesia chemical if they feel uncomfortable during surgical procedures. Other 
anesthesia reagents can also be used, such as Ketamine, Medetomidine and so on. If the 
surgical procedures last more than 2 h, better control of the duration of the anesthesia is 
required, such as inhalation anesthesia method. Whichever method is used, all the 
animals should be applied the same anesthetics.   
9. Sustained release microspheres are good strategy not only for the treatment of 
Alzheimer’s disease, but also for the other neurodegenerative disorders. As mentioned 
in Note 2, GDNF-loaded microsphere has been used to treat Parkinson’s disease.  
10. Learning and memory impairment of Alzheimer’s rats can be tested with other mazes, 
such as Morris water maze and 8-arm maze [53, 54]. Investigators should use different 
behavioral tests to evaluate different animal models. For Alzheimer’s disease animal 
model, the common behavioral test is maze testing. For Parkinson’s disease animal 
model, rotation, reaching task, forelimb asymmetry test and tactile placing are widely 
used to evaluate the behavioral changes [55]. 
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